CABALETTA BIO, INC. (CABA): Price and Financial Metrics


-0.67 (-6.03%)

POWR Rating

Component Grades













Add CABA to Watchlist
Sign Up

Industry: Biotech



in industry

CABA Stock Price Chart Interactive Chart >

Price chart for CABA

CABA Price/Volume Stats

Current price $10.45 52-week high $11.97
Prev. close $11.12 52-week low $0.59
Day low $10.24 Volume 375,999
Day high $11.22 Avg. volume 775,553
50-day MA $7.18 Dividend yield N/A
200-day MA $2.78 Market Cap 303.20M


Cabaletta Bio, Inc. operates as a clinical-stage biotechnology company, which engages in the discovery and development of engineered T cell therapies for B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor to selectively bind and eliminate B cells that produce disease-causing autoantibodies. The company was founded by Michael C. Milone, Steven Nichtberger, and Aimee Payne in 2017 and is headquartered in Philadelphia, PA.

CABA Latest News Stream

Event/Time News Detail
Loading, please wait...

CABA Latest Social Stream

Loading social stream, please wait...

View Full CABA Social Stream

Latest CABA News From Around the Web

Below are the latest news stories about CABALETTA BIO INC that investors may wish to consider to help them evaluate CABA as an investment opportunity.

Cabaletta: Adding To Position For 36% Return Potential After CABA-201 Rally (Technical Analysis)

Investment summary

We are long shares of Cabaletta Bio, Inc. (CABA) having recognized a comfortable return after entering at $2.03 in December last year. Since, the stock has rallied to ~$11, and I'm back to today to share out latest findings on the stock, advocating that the rally has legs to extend. The market continues to show demand for the stock following recent advancements in its CABA-201 pathway. Following this analysis, we are looking for an entry point at ~$10.50–$11.50, buying another 500 shares, and opine there's scope for another 36% upside potential at the current market price to $15.50. Net-net, we rate CABA a buy.


Zach Bristow on Seeking Alpha | January 25, 2023

Autolus Therapeutics Announces Collaboration with Cabaletta Bio for Use of Autolus’ Safety Switch System in Cell Therapies for Autoimmune Disease

LONDON, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces that it has entered into a non-exclusive license agreement with Cabaletta Bio, Inc (Nasdaq: CABA). The agreement allows Cabaletta to incorporate Autolus’ proprietary RQR8 safety switch1 into a cell therapy program for the treatment of autoimmune disease, with an option for Cabaletta to incorporate the

Yahoo | January 9, 2023

Cabaletta Bio to Present at the 41st Annual J.P. Morgan Healthcare Conference

PHILADELPHIA, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseases, today announced that Steven Nichtberger, M.D., Chief Executive Officer, will present at the 41st Annual J.P. Morgan Conference being held in San Francisco, CA on Thursday, January 12th at 7:30 a.m. PT (10:30 a.m. ET). A live webcast of the presentation will b

Yahoo | January 5, 2023

The Zacks Analyst Blog Highlights AVEO Pharmaceuticals, Cabaletta Bio, Verona Pharma and Wave Life Sciences

AVEO Pharmaceuticals, Cabaletta Bio, Verona Pharma and Wave Life Sciences are included in this Analyst Blog.

Yahoo | January 3, 2023

4 Drug Stocks That More Than Doubled This Year

We present four biotech stocks, AVEO, CABA, VRNA and WVE, which despite the current volatile market, have provided more than twice the returns in 2022.

Yahoo | December 30, 2022

Read More 'CABA' Stories Here

CABA Price Returns

1-mo 36.96%
3-mo 511.11%
6-mo 785.59%
1-year 267.96%
3-year -40.73%
5-year N/A
YTD 12.97%
2022 144.06%
2021 -69.63%
2020 -10.67%
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.6368 seconds.